Physicians' Academy for Cardiovascular Education

Intensive glucose-lowering therapy reduces ischaemic heart disease in type 2 diabetes

Literature - Gerstein HC et al., Lancet. 2014


Effects of intensive glycaemic control on ischaemic heart disease: analysis of data from the randomised, controlled ACCORD trial

Gerstein HC, Miller ME, Ismail-Beigi F, et al; ACCORD Study Group
Lancet. 2014 Nov 29;384(9958):1936-41


Increasing glycated haemoglobin A1 (HbA1c) concentrations are related to a higher incidence of ischaemic heart disease (IHD) [1], and people with type 2 diabetes (T2DM) show a two- to three times higher incidence of IHD than people without diabetes, irrespective of other risk factors [2,3].
It has been shown that 10 years of intensive, as compared to standard glucose-lowering therapy reduces the 20-year risk of myocardial infarction (MI) by 15% in patients with newly diagnosed T2DM [4].
The ACCORD trial examined intense (target 6.0%)  vs. standard (target 7.0-7.9%) glucose-lowering therapy in people with established T2DM and additional risk factors for cardiovascular (CV) disease. While the intervention did not affect the primary composite CV outcome [5], non-fatal MI was reduced, but risk of death, specifically from CV causes, was increased after intensive therapy. Exploratory analyses did not reveal a relation between CV mortality and severe hypoglycaemia [6] or the degree or speed of glucose lowering [7].
This article reports the effects of the ACCORD glucose-lowering intervention on indices of IHD, including fatal and non-fatal MI and unstable and new-onset angina, and the degree to which HbA1c levels are related to these effects. After a mean follow-up of 3.7 years, intensive treatment was discontinued after an increase in all-cause and CV mortality had been observed. Patients were then switched to standard therapy. Follow-up then continued for another mean 1.2 years.

Main results

  • Fewer MIs, nonfatal MIs or the composite outcome of any MI or unstable angina (UA) were seen in the intensive therapy group, as compared to the standard therapy group in both follow-up periods.
  • Participants in the intensive group were 20% less likely to experience any MI during the active treatment period, and 16% during the entire follow-up period. Similar observations were done for the composite IHD outcome of MI, UA or coronary revascularisation.
  • Intensive treatment did not affect the incidence of fatal MI or new angina.
  • Cumulative incidence curves for all outcomes were lower with intensive therapy in both follow-up periods.
  • Addition of the HbA1c-concentration measured during active treatment as a time-dependent variable to the hazard analysis, attenuated all significant hazard ratios to neutral, while it did not affect the significance of non-significant hazard ratios.


Intensive glucose-lowering therapy in persons with T2DM was associated with significantly lower 5-year incidence of ischaemic heart disease (13%), any MI (16%), non-fatal MI (19%), coronary revascularisation (16%) and UA (19%). These effects were seen both before participants were switched to standard therapy and after. The observation that correction for HbA1c concentrations cancelled out significant effects, supports the hypothesis that the degree of glucose lowering or some closely related factor accounts for the effect of the intervention on IHD.
These findings are at odds with previous ACCORD observations that the intensive treatment did not reduce fatal MI and death from CV causes. This may be explained by the finding that much of the mortality in the intensive treatment group occurred in people whose HbA1c levels did not decrease from baseline. The relationship between dysglycaemia and IHD requires further study.
Find this article on Pubmed


1 Stratton IM, Adler AI, Neil HA, et al. Association of glycaemia with macrovascular and microvascular complications of type 2 diabetes (UKPDS 35): prospective observational study. BMJ 2000; 321: 405–12.
2 The Emerging Risk Factors Collaboration. Diabetes mellitus, fasting blood glucose concentration, and risk of vascular disease: a collaborative meta-analysis of 102 prospective studies. Lancet 2010;
375: 2215–22.
3 Seshasai SR, Kaptoge S, Thompson A, et al, for the Emerging Risk Factors Collaboration. Diabetes mellitus, fasting gluco 4 Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med 2008; 359: 1577–89.
5 Gerstein HC, Miller ME, Byington RP, et al, for the Action to Control Cardiovascular Risk in Diabetes Study Group. Eff ects of intensive glucose lowering in type 2 diabetes. N Engl J Med 2008; 358: 2545–59.
6 Riddle MC, Ambrosius WT, Brillon DJ, et al, for the Action to Control Cardiovascular Risk in Diabetes Investigators. Epidemiologic relationships between A1C and all-cause mortality during a median 3.4-year follow-up of glycemic treatment in the ACCORD trial. Diabetes Care 2010; 33: 983–90.
7 Bonds DE, Miller ME, Bergenstal RM, et al. The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study. BMJ 2010; 340: b4909.

Share this page with your colleagues and friends: